Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 1, Pages 186
Publisher
MDPI AG
Online
2020-01-13
DOI
10.3390/cancers12010186
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Y6, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance
- (2019) Rui-Qiang Zhao et al. Frontiers in Pharmacology
- ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance
- (2019) Xudong Gao et al. OncoTargets and Therapy
- Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells
- (2019) Zhuo-Xun Wu et al. BIOCHEMICAL PHARMACOLOGY
- Capmatinib for the treatment of non-small cell lung cancer
- (2019) Johan Filip Vansteenkiste et al. Expert Review of Anticancer Therapy
- The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model
- (2018) Na Zhan et al. GENE EXPRESSION
- Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
- (2018) Mohamed Bouattour et al. HEPATOLOGY
- Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
- (2018) David E. Gerber et al. LUNG CANCER
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance
- (2018) Ning Ji et al. BIOCHEMICAL PHARMACOLOGY
- Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
- (2018) Wei Zhang et al. Frontiers in Pharmacology
- VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
- (2018) Ning Ji et al. Frontiers in Pharmacology
- Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer
- (2018) Yun-Kai Zhang et al. CANCER LETTERS
- Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
- (2017) Nicola Personeni et al. Oncotarget
- Inhibiting ABCG2 by Ko143 May Enhance the Efficacy of Irinotecan Treatment in Colon Cancer
- (2015) Hoang Dinh Tuy et al. Clinical Gastroenterology and Hepatology
- Molecular mechanisms of drug resistance and its reversal in cancer
- (2015) Melis Kartal-Yandim et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
- (2015) Qingfeng Xiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
- (2014) Qingcheng Mao et al. AAPS Journal
- Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter-Mediated Drug Resistance
- (2014) A. Aoyama et al. MOLECULAR CANCER THERAPEUTICS
- GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
- (2013) Lily L. Remsing Rix et al. ACS Chemical Biology
- A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
- (2013) A Santoro et al. BRITISH JOURNAL OF CANCER
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
- (2012) Assunta Sgambato et al. CURRENT PHARMACEUTICAL DESIGN
- Effects of DMSO on gene expression in human and rat hepatocytes
- (2011) Kayo Sumida et al. HUMAN & EXPERIMENTAL TOXICOLOGY
- Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression
- (2011) Takeo Nakanishi et al. Chinese Journal of Cancer
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started